Clinical Trials Logo

Clinical Trial Summary

This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation, who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a vitamin K antagonist.

The first question is whether replacement of the vitamin K antagonist by rivaroxaban is able to slow progression of vascular calcification. The second question is whether addition of vitamin K2 to rivaroxaban can further slow down or even halt the progression of vascular calcification.


Clinical Trial Description

The present study targets dialysis patients with non-valvular atrial fibrillation requiring treatment with vitamin K antagonists. It addresses the question whether replacement of the vitamin K antagonist by rivaroxaban is able to slow progression of vascular calcification (VC). The second research question is whether addition of vitamin K2 to rivaroxaban can further beneficially affect the progression of VC. Two non-invasive methods are used to evaluate the impact of interventions on the progression of VC: i.e. coronary artery calcification (CAC) and pulse wave velocity (PWV) measurements. The detection of CAC is predictive for the presence of obstructive coronary artery disease and future coronary events. VC and stiffening of the central elastic-type arteries are independent predictors of cardiovascular morbidity and mortality in hemodialysis patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02610933
Study type Interventional
Source Onze Lieve Vrouw Hospital
Contact
Status Completed
Phase Phase 4
Start date November 2015
Completion date January 23, 2019

See also
  Status Clinical Trial Phase
Completed NCT03960437 - The Effect of Etelcalcetide on CKD-MBD Phase 2
Recruiting NCT04983875 - Mammography and Breast Arterial Calcification: An Information-Sharing Trial N/A
Completed NCT03292029 - Pilot Medical Evaluation of the T50 Test N/A
Completed NCT02561299 - Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study N/A
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Active, not recruiting NCT02598635 - Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis Phase 4
Completed NCT00183001 - Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Phase 3
Completed NCT04114695 - Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease
Not yet recruiting NCT03169400 - Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) N/A
Completed NCT03314493 - Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients Phase 3
Completed NCT03839732 - Observer Variability in Scoring Abdominal Aortic Calcifications and Vertebral Morphometry
Completed NCT02542319 - Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease Phase 2
Completed NCT00481364 - Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients Phase 3
Completed NCT00694824 - Vascular Calcification's Risk Factors in Haemodialysis Patients
Recruiting NCT01364688 - Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease Phase 2
Completed NCT01675206 - Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients Phase 3
Active, not recruiting NCT03937349 - Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
Not yet recruiting NCT05720156 - Immunomodulatory Effects of PCSK9 Inhibition
Completed NCT02719665 - THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease N/A
Recruiting NCT04753593 - Use of Discarded Surgery Human Tissue Specimens for Basic Science Research